Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossMedicare Advantage · Administrative · Pharmacy · NJ · Neurology, Pediatrics, PharmacyLow impact

MA08.086d, Nusinersen (Spinraza®)

Effective date
Not stated in the notice
Identified
Jun 19, 2026

Summary

Independence Blue Cross has reissued Medical Policy MA08.086d for Nusinersen (Spinraza®) as part of its annual review process. The policy establishes coverage criteria for this spinal muscular atrophy treatment under Medicare Advantage plans, requiring genetic confirmation of 5q-SMA, prescription by a neurologist/physiatrist, and documented motor function improvement on standardized scales for continuation therapy. No substantive coverage changes were noted in this reissuance.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

Action · 4 steps
01No immediate action required.
02This is a routine annual policy reissuance with no substantive changes to coverage criteria, dosing, or billing requirements.
03Billing team should verify that current authorizations and claims processing for nusinersen (Spinraza®) under HCPCS code J2326 continue to comply with the existing medical necessity criteria: genetic testing confirmation, provider qualification (neurologist or physiatrist with neuromuscular subspecialty), appropriate dosing regimens (lower: 12 mg maintenance every 4 months; higher: 28 mg maintenance every 4 months), and documented motor function response using standardized measurement scales (HINE, CHOP-INTEND, or HFMSE).
04No workflow changes are necessary.

Codes mentioned

J2326G12.0G12.1

Original notice

MA08.086d, Nusinersen (Spinraza®)
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
MA08.086d, Nusinersen (Spinraza®)LowEffective Jan 1, 2024 · PharmacyMA08.086d, Nusinersen (Spinraza®)LowNo effective date · Pharmacy08.01.36f, Therapies for Spinal Muscular Atrophy Nusinersen (Spinraza®) and Onasemnogene abeparvovec-xioi (Zolgensma®)MediumEffective Mar 23, 2026 · PharmacyMA08.086e, Nusinersen (Spinraza®)MediumEffective Sep 14, 2026 · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesNJ policy changesNeurologyPediatricsPharmacyCode J2326Code G12.0Code G12.1

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account